Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?

Since the time questions arose on cardiovascular safety of Rosiglitazone, FDA has suggested guidelines on conduct of studies on anti-diabetic drugs so as to prove that the cardiovascular risk is acceptable. Based on the cardiovascular risks of pre-approval clinical trials, guidelines have been made...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Mathew, Gopalakrishnan Unnikrishnan, Ambika, Kalra, Sanjay, Nair, Tiny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990725/
https://www.ncbi.nlm.nih.gov/pubmed/27543483
http://dx.doi.org/10.1016/j.ihj.2016.02.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990725/
https://www.ncbi.nlm.nih.gov/pubmed/27543483
http://dx.doi.org/10.1016/j.ihj.2016.02.017

Ejemplares similares